Binary Genomics is developing a DNA-based blood test for pan-cancer detection and monitoring. Our test captures unique epigenetic fingerprints from each patient’s tumor, regardless of cancer type, including lower-prevalence cancers that are often deprioritized in other tests. Gene silencing by methylation of promoters is a key epigenetic mechanism of carcinogenesis. Binary Genomics’ proprietary technology captures abnormally methylated promoter DNA fragments based on high methylation density, rather than pre-specified sequence. Applications include earlier cancer diagnosis, surveillance of residual or recurrent disease, and real-time monitoring of treatment efficacy. Ultimately, this will provide a broad-spectrum diagnostic tool to improve patient outcomes.